[Skip to Content]

Use of Avastin (bevacizumab) in age related macular degeneration

Dec 15
2014

Updated Statement from The Royal College of Ophthalmologists In 2011 a working group of The Royal College of Ophthalmologists released a statement regarding the use of Avastin (bevacizumab) in medical ophthalmology. It found that Avastin and Lucentis (ranibizumab) were equally effective in the treatment of neovascular age-related macular degeneration (AMD) and that there was no

  • 15 December 2014

RCOphth calls for review of Avastin for use in AMD treatment

Nov 19
2014

Professor Carrie MacEwen and Professor Andrew Lotery co-author the editorial ‘What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?’, published online on BMJ, calls for UK regulatory bodies to review and appraise use of bevacizumab for use in AMD treatment. Ranibizumab (Lucentis), the first drug used to treat this

  • 19 November 2014

Obituary – Professor Peter Eustace

Nov 12
2014

Professor Peter Eustace FRCophth Professor Peter Eustace was a Consultant Ophthalmic Surgeon with a special interest in Neuro-ophthalmology. He studied Medicine in University College Galway where he met his beloved wife Margaret. His post graduate training was undertaken in Birmingham in general practice initially and subsequently in Ophthalmology. He was appointed to the Mater Hospital

  • 12 November 2014

Survey finds nearly 70% of patients waiting too long for treatment

Nov 12
2014

A survey of ophthalmologists found that nearly 70% of patients with wet age-related macular degeneration (AMD) had to wait more than the recommended two weeks for their first sight-saving injection. Many also wait too long for follow up treatment. The Royal College of Ophthalmologists and the Macular Society say their research shows that more resources

  • 12 November 2014

President’s foreword for RNIB Report ‘Real Patients Coming to Real Harm’ Wales

Nov 12
2014

A substantial part of the workload of ophthalmology services is the care of long term conditions such as glaucoma, diabetic retinopathy and age-related macular degeneration. These conditions all become increasingly common with advancing age and all require timely recognition and treatment in order to avoid preventable sight loss.  Unfortunately, clinical services for these long-term conditions

  • 12 November 2014